公司資料
Ascendis Pharma 股價、新聞與催化劑
- 股票代碼:
- ASND
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Denmark
股票表現
253.29 USD (-0.60%)
收盤價
最後更新: 2026年8月21日
13.4B USD
市值
股價為何變動
As of Aug 21, 2026, ASND closed down 0.60% at $253.29. No new same-company headline was identified in the current news window.
公司概覽
TransCon Technology
Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology.
Commercial Endocrinology Portfolio
YORVIPATH is a parathyroid-hormone replacement therapy for chronic hypoparathyroidism. SKYTROFA is a once-weekly growth-hormone therapy, and YUVIWEL is approved in the United States for children with achondroplasia.
Growth-Disorder Development
Ascendis is studying TransCon CNP in infants with achondroplasia and in hypochondroplasia. It is also evaluating TransCon CNP combined with TransCon hGH to address growth and skeletal complications.
Oncology Program
Onvapegleukin alfa is a long-acting IL-2 beta/gamma agonist in Phase 1/2 development, including combination treatment for platinum-resistant ovarian cancer.
未來催化劑
- European regulatory decision for YUVIWEL in the fourth quarter of 2026.
- Initiation of a Phase 3 TransCon CNP study in hypochondroplasia in the second half of 2026.
- Initiation of a Phase 3 TransCon CNP plus TransCon hGH study in pediatric achondroplasia in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。